ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter introduces an innovative approach to sepsis treatment by directly filtering harmful pathogens from the bloodstream. Utilizing a proprietary affinity technology, this device rapidly captures bacteria and fungi, including drug-resistant strains like Pseudomonas and Candida, which are often difficult to treat with conventional antibiotics. This non-pharmacological method offers a novel solution for critically ill patients, especially those recovering from cardiac surgeries such as infective endocarditis, where bloodstream infections can be life-threatening.

In a clinical study conducted at Papardo Hospital in Italy, the Seraph 100 was used on septic patients following cardiac surgery. The device demonstrated rapid pathogen reduction within four hours of treatment, resulting in improved clinical markers such as decreased inflammation, stabilized blood pressure, and reduced need for vasopressor medications. Patients treated with the filter also experienced shorter stays in intensive care and significantly fewer cases of acute kidney injury requiring dialysis, a common complication of sepsis. These findings highlight the device’s potential to improve patient outcomes and reduce healthcare burdens associated with severe infections.

The importance of the Seraph® 100 lies in its ability to address critical gaps in sepsis care by providing immediate and effective pathogen clearance, which can lead to faster recovery and lower complication rates. This breakthrough technology not only supports the management of complex infections but also offers a promising tool for combating resistant pathogens. As sepsis remains a leading cause of mortality worldwide, the Seraph 100 represents a major advancement that could transform standard treatment protocols, improving survival rates and quality of life for vulnerable patients after cardiac surgery and beyond.

MedTech Spectrum's Summary

Rapid Pathogen Removal: The Seraph® 100 device significantly reduces bloodstream pathogen load within hours, offering a fast-acting solution for sepsis treatment in post-cardiac surgery patients.

Improved Clinical Outcomes: Patients treated with the filter showed lower inflammation, more stable vital signs, shorter ICU stays, and reduced incidence of acute kidney injury compared to those untreated.

Critical Tool Against Superbugs: By effectively removing drug-resistant organisms like Pseudomonas and Candida, the device provides a vital non-antibiotic option for combating severe infections and improving patient survival.